{"id":"low-dose-dopamine-low-dose-furosemide","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Tachycardia"},{"rate":null,"effect":"Hypokalemia"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Arrhythmias"}]},"_chembl":{"chemblId":"CHEMBL2108580","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dopamine at low doses (1–3 mcg/kg/min) activates dopamine-1 (DA1) receptors on renal vasculature and tubules, causing vasodilation and increased glomerular filtration without systemic vasoconstriction. Furosemide is a loop diuretic that inhibits the Na-K-2Cl cotransporter in the thick ascending limb, promoting sodium and water excretion. The combination is designed to synergistically improve renal function by enhancing both renal perfusion (dopamine) and diuretic response (furosemide) while minimizing systemic hemodynamic compromise.","oneSentence":"Low-dose dopamine stimulates renal dopamine receptors to promote natriuresis and renal blood flow, while low-dose furosemide enhances diuresis, together improving renal perfusion and urine output in acute kidney injury or cardiorenal syndrome.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:53:21.158Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute kidney injury with oliguria"},{"name":"Cardiorenal syndrome"},{"name":"Acute decompensated heart failure with renal dysfunction"}]},"trialDetails":[{"nctId":"NCT01140399","phase":"PHASE4","title":"REWORD-HF REverse WOrsening Renal Function in Decompensated Heart Failure","status":"TERMINATED","sponsor":"Niguarda Hospital","startDate":"2011-02","conditions":"Acute Decompensated Heart Failure","enrollment":10},{"nctId":"NCT01060293","phase":"PHASE4","title":"Dopamine in Acute Decompensated Heart Failure II","status":"TERMINATED","sponsor":"Larissa University Hospital","startDate":"2009-07","conditions":"Acute Decompensated Heart Failure","enrollment":161},{"nctId":"NCT00937092","phase":"PHASE4","title":"Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial","status":"UNKNOWN","sponsor":"Larissa University Hospital","startDate":"2009-01","conditions":"Acute Heart Failure","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"low-dose dopamine + low-dose furosemide","genericName":"low-dose dopamine + low-dose furosemide","companyName":"Larissa University Hospital","companyId":"larissa-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Low-dose dopamine stimulates renal dopamine receptors to promote natriuresis and renal blood flow, while low-dose furosemide enhances diuresis, together improving renal perfusion and urine output in acute kidney injury or cardiorenal syndrome. Used for Acute kidney injury with oliguria, Cardiorenal syndrome, Acute decompensated heart failure with renal dysfunction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}